Effects of Dexmedetomidine on Clinical Outcomes and Renal Function after CABG by Rahab, Mehdi et al.
  Journal of Cellular & Molecular Anesthesia (JCMA)  
Vol 6, No 1, Winter 2021 
31 
Original Article  
 
 
Effects of Dexmedetomidine on Clinical Outcomes and Renal 
Function after CABG 
 
Mehdi Rahab1, Evaz Heydarpour2 , Ziae Totonchi2* , Naser Kachoueian3 , Sam Zeraatiannejad Davani4
, Mehrdad Mesbah Kiaei5 , Mohammad Javad Mehrabanian6 6, Masoumeh Panahi7, Parnian Ahmadvand1, 





Background: This study was carried out to determine the effects of 
dexmedetomidine on clinical outcomes and renal function after coronary artery 
bypass grafting (CABG) to address the increased rate of CABG? and the 
importance of modification in stress responses and control of adverse effects on 
renal function and with the aim of cost reduction.  
Materials and Methods: This double-blind randomized clinical trial was 
carried out with the participation of 129 subjects under elective CABG in Rajaei 
Heart Center, Tehran, Iran in 2017. Patients were randomly assigned to four 
groups with simple randomization including one placebo (normal saline 
infusion) group and three dexmedetomidine groups; 0.5 µg/kg/h on CPB, 0.5 
µg/kg/h in 24 hours, and 0.75 µg/kg/h in 24 hours. The blood pressure, blood 
urea nitrogen (BUN), serum creatinine, transfused blood volume, urine volume, 
and hemofiltration on pump and lactate were assessed at different time intervals.  
Results: Results showed more stability especially in central venous pressure 
(CVP) (p=0.001) and systolic blood pressure (p=0.006) in the groups 
receiving dexmedetomidine 0.75 µg/kg/h per 24 hours. But diastolic blood 
pressure and heart rate were the same across the groups (p>0.05). All other 
variables including hepatic and renal function tests were the same across the 
groups (P>0.05).  
Conclusion: Overall, according to the obtained results in the current study, it 
may be concluded that dexmedetomidine would have some promising effects 
on hemodynamic stability but there are no obvious renoprotective effects for 
this medication.  
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Cardiovascular disease is a common cause of 
morbidity and mortality is seen in approximately 17 
million subjects in the United States (1). Acute kidney 
disorders in subjects undergoing cardiac surgery are a 
common postoperative problem in subjects undergoing 
coronary artery bypass graft (CABG). The prevalence 
rate of acute kidney injury varies from 3 to 30 percent 
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(2-4) and nearly 0.5 to 3 percent in cases that would 
require dialysis (5-8). Known risk factors include age, 
BMI, lipid-lowering agents, hypertension, peripheral 
vascular diseases, chronic lung diseases, hemoglobin 
concentration, previous cardiac surgery, emergency 
heart surgery, and any type of operation which may 
increase the risk of acute kidney injury (8-9). It is also 
related to ward stay in patients undergoing coronary 
artery bypass grafting (CABG) (5). Furthermore, in 
cases with dialysis requirements, it may result in a high 
(60%) mortality rate (4, 5).  
In this research, with regards to the increased 
rate of CABG and the importance of modification in 
stress responses and control of adverse effects on renal 
function, and with the aim of cost reduction we carried 
out this study to determine the effects of 
dexmedetomidine on clinical outcomes and renal 
function after CABG. 
 
Methods 
This double-blind randomized clinical trial was done 
with the participation of 129 subjects under elective 
CABG in Rajaei Heart Center, Tehran, Iran in 2017. 
Inclusion criteria were the signing of informed consent 
forms, lack of previous renal disorder, and no diuretic 
use, lack of peripheral vascular disease or chronic lung 
disorders, and lack of any previous cardiac surgery. 
The IRCT code was IRCT20170912036157N1. 
In all patients monitoring for venous and arterial 
blood pressure was done at the entry to the operation 
room. Anesthesia induction was performed using the 
same method and drugs. Patients were randomly 
assigned into four groups with block randomization 
including one placebo (normal saline infusion) group 
(A) and three dexmedetomidine groups; 0.5 µg/Kg/h 
from induction of anesthesia till the end of CPB (B), 
0.5 µg/Kg/h from induction of anesthesia for 24 hours 
(C), and 0.75 µg/Kg/h from induction of anesthesia for 
24 hours (D). When the mean arterial pressure reached 
lessthan 50 mmHg and the heart rate decreased to less 
than 60 per minute the drug was discontinued for 30 
minutes and fluid administration was done. After 
normalization of blood pressure and heart rate, the 
infusion was initiated again. 
The tidal volume was set at 10 ml/kg with the 
optimal respiratory rate for age by anesthesia machine 
to maintain PaCO2 between 30 and 35 mmHg under 
mechanical ventilation. The priming solution of the 
bypass machine includes ringer-lactate 800 ml, 
mannitol 20% 100 ml, and heparin 5000 units for all 
patients. The mean arterial blood pressure was 
maintained between 40 and 70 mmHg. Total bypass 
time and aorta cross-clamp time were recorded. 
Hypotension and hypertension during pump state were 
treated with phenylephrine and Trinitroglycerine 
(TNG), respectively; besides, the used doses were 
recorded. The other variables including age, gender, 
blood pressure, blood urea nitrogen (BUN), serum 
creatinine, transfused blood volume, urine volume, and 
hemofiltration on pump and lactate were assessed at 
different time intervals according to lab data and 
medical documents. All assessments were done by a 
single-blinded trained nurse. 
Data analysis was performed on 130 subjects 
including 42 patients in the control group and 87 
subjects in the three intervention groups. Data analysis 
was performed by SPSS (version 13.0) software 
[Statistical Procedures for Social Sciences; Chicago, 
Illinois, USA]. Chi-Square, ANOVA, and repeated-
measure-ANOVA tests were used and were considered 
statistically significant at P values less than 0.05. 
 
Results 
The age and body mass index (BMI) were matched 
across the groups (Table 1). Previous medical history 
was also alike across the groups (Table 2). Except for 
operation time and intensive care unit (ICU) stay the 
other time intervals were matched across the groups (Table 
3). As shown in Table 4 the utilized inotrope drugs in the 
operating room and ICU were alike across the groups 
(P > 0.05). As demonstrated in Table-5 all measured 
biochemical and arterial blood gas (ABG) and clinical 
results were matched across the groups (p>0.05). 
However, the heart rate and diastolic blood pressure 
had no significant alteration difference across the 
groups whereas the systolic blood pressure and central 
venous pressure (CVP) alteration differed significantly 
in the groups (Table 6) with better measures in 
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As can be seen, the results showed more stability especially in CVP and systolic blood pressure in the 
Table 1: The age and BMI distribution across the groups. 
 
Group   Age Body mass index 
Placebo (A) 
Mean 56.90 26.69 
Std. Deviation 13.36 4.82 
0.5 micro on CPB (B) 
Mean 61.56 26.74 
Std. Deviation 11.45 4.68 
0.5 micro 24 h (C) 
Mean 58.69 26.87 
Std. Deviation 11.66 4.49 
0.75 micro 24 h (D) 
Mean 57.00 26.95 
Std. Deviation 13.08 4.56 
 
Table 2: Background diseases across the groups. 
 
 Group 
  Placebo (A) 0.5 micro on CPB (B) 0.5 micro 24 h (C) 0.75 micro 24 h (D) 
  Count Percent Count Percent Count Percent Count Percent 
Hypertension 19 30.6% 21 33.9% 11 17.7% 11 17.7% 
Diabetes 6 21.4% 0 .0% 11 39.3% 11 39.3% 
Smoking  14 45.2% 8 25.8% 4 12.9% 5 16.1% 
Thyroid Disease 0 .0% 0 .0% 0 .0% 2 100.0% 
CVA 2 28.6% 0 .0% 1 14.3% 4 57.1% 
Hyperlipidemia 10 34.5% 7 24.1% 7 24.1% 5 17.2% 
Opiate/drug abuse 16 51.6% 8 25.8% 4 12.9% 3 9.7% 
 
Table 3: Time intervals in the study groups. 
 
Group   
CPB 








Mean 81.80 44.04 188.18 14.89 36.02 790.51 
Std. 
Deviation 
32.40 18.20 113.56 4.84 18.10 438.72 
0.5 micro on 
CPB (B) 
Mean 87.96 44.81 264.09 17.87 51.54 689.58 
Std. 
Deviation 
41.66 21.92 66.93 8.63 26.03 207.98 
0.5 micro 24 h 
(C) 
Mean 88.90 54.56 4.62 60.74 34.00 745.16 
Std. 
Deviation 
38.19 23.74 1.02 249.53 27.94 310.20 
0.75 micro 24 h 
(D) 
Mean 83.87 50.08 28.20 77.15 36.73 776.08 
Std. 
Deviation 
26.12 18.89 59.10 298.90 24.931 544.78 
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receiving Dexmedetomidine 0.75µg/kg/h for 24 hours. 
But diastolic blood pressure and heart rate were the 
same across the groups. All other variables including 
hepatic and renal function tests were the same across 
the groups. 
The study by Zhai et al (24) revealed that 
dexmedetomidine infusion would result in 
renoprotective effects in patients undergoing CABG 
procedures leading to decreased rate of acute kidney 
injury due to decreased activity of super-oxide 
dismutase enzyme. But in our study, none of the factors 
of BUN and creatinine differed significantly in the 
different groups. This difference may be due to the  
 
 
Table 5: Utilized inotrope agents across the groups. 
 Group 
  
Placebo (A) 0.5 micro on CPB (B) 0.5 micro 24 h (C) 0.75 micro 24 h (D) 









Preoperative ALT 24.38 13.29 26.71 16.13 36.11 65.43 21.22 7.15 
Postoperative ALT 34.67 55.76 26.75 13.94 21.22 10.72 23.12 14.53 
ALT24hr 29.26 25.81 51.33 114.18 23.22 20.16 20.33 11.17 
ALT48hr 20.18 12.16 88.13 328.44 54.00 187.76 196.26 785.55 
Preoperative AST 22.86 9.37 20.89 7.98 25.22 14.57 21.08 7.10 
Postoperative AST 46.26 88.15 33.90 14.29 42.97 27.16 42.33 14.65 
AST24hr 65.14 153.25 71.40 171.27 55.69 52.24 46.58 21.96 
AST48hr 36.09 27.22 89.16 272.18 96.88 285.62 743.42 3084.35 
Preoperative HGB 13.36 1.60 13.30 1.87 12.22 2.26 12.87 2.39 




Placebo (A) 0.5 micro on CPB (B) 0.5 micro 24 h (C) 0.75 micro 24 h (D) 
Count Percent Count Percent Count Percent Count Percent 
Epinephrine OR 11 31.4% 9 25.7% 10 28.6% 5 14.3% 
Norepinephrine 
OR 
1 50.0% 0 .0% 0 .0% 1 50.0% 
Milrinone OR 0 .0% 1 50.0% 1 50.0% 0 .0% 
Epinephrine CU 15 37.5% 7 17.5% 13 32.5% 5 12.5% 
Norepinephrine 
ICU 
1 33.3% 0 .0% 1 33.3% 1 33.3% 
Dopamine ICU 0 .0% 0 .0% 1 100.0% 0 .0% 
Dobutamine ICU 0 .0% 0 .0% 1 100.0% 0 .0% 
Milrinone ICU 0 .0% 1 33.3% 2 66.7% 0 .0% 
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Postoperative HGB 10.25 1.34 10.35 1.24 9.97 1.45 68.19 284.11 
HGB24hr 9.52 1.87 9.89 1.26 9.48 1.80 10.12 1.48 
HGB48hr 9.47 1.20 10.04 1.36 9.23 1.05 9.75 2.43 
Preoperative Cr .96 .21 .98 .30 1.11 .24 1.23 .26 
Postoperative Cr .87 .23 1.52 2.50 1.00 .28 1.09 .27 
Cr24hr .90 .28 .93 .24 1.17 .31 1.17 .29 
Cr48hr .86 .31 .89 .35 1.03 .30 1.19 .64 
Preoperative BUN 16.15 6.56 19.09 8.54 19.27 7.97 18.04 6.22 
Postoperative BUN 18.88 8.06 17.84 5.66 21.31 6.87 21.63 11.26 
bun24HR 20.31 6.52 26.22 28.76 24.41 8.24 23.92 9.35 
BUN48hr 19.78 8.34 22.90 10.85 22.77 9.94 23.58 10.02 
Preoperative Lactate 1.04 .44 .97 .37 .74 .44 .94 .26 
Postoperative Lactate 7.53 33.30 5.10 18.60 2.36 2.02 2.14 1.31 
lactat24hr 2.56 1.56 2.85 1.95 1.83 1.30 3.40 4.78 
lactat48hr 1.40 .28 . . 1.13 .44 4.50 7.60 
Diuresis OR 662.50 511.88 785.31 660.55 1116.13 650.31 1333.91 1266.22 
Diuresis First day 2102.57 749.77 2283.33 769.05 2385.00 824.63 2615.42 999.37 
duresis2day 2369.12 735.69 2292.19 569.11 2720.31 590.91 2508.33 619.37 
duresis3dat . . . . 1667.00 1526.98 2000.00 . 
hemofiltration 1942.59 591.07 1645.65 603.95 1550.00 441.59 1783.33 567.16 
Preoperative Hemoglobin 13.46 1.46 13.30 1.87 12.54 1.82 12.78 2.19 
Hemoglobin ICU Entry 14.99 20.76 13.58 18.45 9.98 1.49 10.16 1.68 
hemoglobin24hr 9.46 1.83 9.89 1.26 9.25 1.20 9.82 1.36 
hemoglobin48hr 9.53 1.21 10.04 1.36 9.55 .99 10.08 1.67 
Preoperative K 4.86 5.16 3.87 .61 3.88 .52 3.76 .57 
K30min 5.55 5.15 5.36 1.22 4.35 .89 4.20 .93 
Postoperative K 4.83 .83 5.03 .79 4.36 .71 4.12 .70 
K ICU entry 4.74 .88 5.03 .79 5.29 5.49 4.16 .59 
k12hr 4.32 .58 4.33 .47 4.33 .46 4.21 .51 
k24hr 4.98 4.99 4.27 .53 4.11 .46 4.01 .44 
Preoperative Na 144.30 4.22 144.03 4.61 136.21 23.39 144.46 5.36 
Na30min 136.12 4.72 135.19 3.87 136.25 4.53 141.08 6.59 
Postoperative Na 133.88 5.77 135.03 4.71 135.80 4.36 139.00 3.70 
Na ICU entry 140.74 4.88 140.75 5.48 137.84 4.06 139.29 6.04 
Na12hr 142.55 5.50 143.94 5.84 141.63 24.33 143.71 5.10 
Na24hr 138.60 21.93 133.31 31.94 141.47 6.44 140.88 5.15 
HCO3preop 23.34 3.47 22.59 3.38 22.77 2.67 21.74 2.30 
HCO30min 21.15 2.25 20.03 3.20 20.97 2.68 20.83 2.58 
HCO3postop 20.63 2.80 21.19 2.49 19.20 2.36 19.93 1.79 
HCO3icuENTERANCE 19.48 2.18 20.09 2.22 22.50 17.98 19.25 1.89 
HCO12hr 20.24 2.68 21.00 2.27 19.63 2.95 19.54 2.57 
HCO24HR 21.55 3.19 21.88 3.05 22.06 2.95 22.04 3.34 
Preoperative PCO 34.37 5.42 33.74 7.92 34.77 5.12 33.09 4.77 
PCO30min 35.90 6.45 36.81 6.70 34.78 5.29 32.92 5.12 
Postoperative PCO 33.90 6.01 35.69 4.37 34.68 7.86 35.38 6.13 
PCO ICU entry 34.69 7.39 33.28 6.84 37.59 23.17 34.35 5.77 
PCO22hr 33.48 6.10 36.47 5.46 34.84 5.73 33.71 4.72 
PCO24hr 34.64 5.31 35.38 6.95 38.34 7.69 34.96 5.90 
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O2SAT preop 95.26 3.19 93.03 10.33 94.26 4.02 93.48 12.69 
o2sat30MIN 99.10 4.36 99.75 .44 100.00 .00 99.88 .45 
O2SAT postop 99.03 1.97 100.28 5.50 98.56 1.45 98.69 1.30 
o2satICUENTERANCE 95.43 3.97 93.72 15.67 97.69 1.71 97.87 1.49 
O2SAT12hr 96.57 2.24 95.50 2.50 97.50 1.41 97.13 1.94 
O2SAT24hr 94.43 7.24 91.22 9.88 92.91 9.24 94.33 8.66 
po2PREOP 103.97 70.34 98.53 60.79 84.06 40.69 95.57 44.13 
po230MIN 267.85 102.42 267.00 71.12 321.83 105.82 336.42 87.28 
po2postop 225.20 112.38 198.79 63.34 181.28 72.56 181.40 85.86 
po2icuENTERANCE 104.36 49.12 100.97 27.05 143.06 51.84 143.21 56.12 
po212hr 98.75 31.88 89.91 27.07 120.16 43.62 118.63 39.67 
po224hr 87.60 27.28 76.63 18.18 90.59 34.07 110.67 57.36 
Preoperative pH 7.44 .04 7.43 .06 237.67 1281.95 10.79 16.18 
PH30min 7.38 .06 7.35 .06 7.40 .05 19.85 60.95 
Postoperative pH 7.40 .07 7.38 .05 7.34 .10 16.80 36.57 
pH ICU entry 7.37 .07 7.39 .07 7.38 .08 12.26 24.01 
PH12hr 7.38 .05 7.37 .05 30.14 128.81 12.15 23.40 
PH24hr 7.40 .04 7.40 .05 30.37 130.04 8.64 6.04 
 
 
dispersion of the data for kidney function tests in the 
three groups that received dexmedetomidine. 
During CABG the non-pulsation blood flow, 
emboli, catecholamine release, inflammatory 
mediators, and hemoglobin released from destructed 
blood cells would result in increased renal vessel 
resistance and decreased glomerular filtration rate from 
25 to 75 percent (9). Dexmedetomidine is a selective 
alpha-2-adrenergic agonist of sedation, analgesia, and 
anti-anxiety effects plus it has useful effects for 
reduction of anesthetics and increase of hemodynamic 
stability (6, 7). Regarding the high application of this 
drug in CABG procedures, considerable effects in the 
reduction of postoperative pulmonary and cerebral 
injuries are reported (8-10).  
It seems that stimulation of Alpha-2b receptor 
in locus coeruleus would result in a dose-dependent 
reduction of norepinephrine leading to increased renal 
blood flow (11). Also, it may decrease stress responses 
to surgery trauma with direct and indirect effects as an 
alpha agonist. Besides, dexmedetomidine may result in 
improvement in blood flow of the kidneys due to 
decreased pre-synaptic norepinephrine leading to 
vasodilatation (12-15). However, drug safety has not 
yet been established but there are some reports in 
animal models of decreased ischemia-reperfusion 
injury in kidneys in an increased urinary output (11-
13). Väisänen et al (14) assessed the effect of 
dexmedetomidine on stress response in dogs. They 
found that premedication with dexmedetomidine 
would result in a reduction of preoperative stress 
hormones and also leads to decreased sympathetic 
activity by catecholamine stability. This is the main 
cause of a better hemodynamic status especially for 
systolic blood pressure in our study. 
The study by Balkanay et al (15) demonstrated 
that dexmedetomidine would have a dose-dependent 
effect, especially for renoprotection. Such dose-
dependent effects were seen in our study especially 
regarding CVP and systolic blood pressure. The study 
by Mukhtar and colleagues (16) showed that 
dexmedetomidine administration in children 
undergoing congenital heart surgery would result in a 
reduced rate of hemodynamic responses as well as 
systolic blood pressure in adults. Similar studies have 




Overall, according to the obtained results in the current 
study, it may be concluded that dexmedetomidine 
would have some promising effects on hemodynamic 
stability but there are no obvious renoprotective effects 
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with this medication. However further studies with 
larger sample size and control for possible 
confounding factors would result in more pieces of 
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